Galectin-3 May Serve As a Potential Marker for Diagnosis and Prognosis in Papillary Thyroid Carcinoma: a Meta-analysis

Overview

Journal Onco Targets Ther

Publisher Dove Medical Press

Specialty Oncology

Date 2016 Feb 10

PMID 26858526

Citations 23

Authors

Weiwei Tang

Congwei Huang

Chongyin Tang

Jin Xu

Hanjin Wang

Affiliations

Soon will be listed here.

Abstract

Background: Galectin-3 is a member of the beta-galactoside-binding protein family and functions as a modulator of cell growth through galactoside-binding protein correlated with the occurrence and metastasis of papillary thyroid carcinoma (PTC).

Methods: A systematic review of published articles on Web of Science and PubMed was performed. After establishing inclusion and exclusion criteria, nine articles were selected. Three studies referred to galectin-3 expression in PTC and non-PTC patients. Three studies referred to galectin-3 expression in PTC patients with lymph node metastasis (LNM) and without LNM. Three studies referred to galectin-3 expression in both PTC (with and without LNM) and non-PTC patients. Data analysis was performed by using RevMan5.2 software.

Results: A total of 424 patients from six eligible studies that provided data about galectin-3 expression in PTC and non-PTC patients were included. A total of 378 patients from six eligible studies that provided data about galectin-3 expression in PTC with LNM and without LNM were included. Immunohistochemistry technique was used in all the studies. Galectin-3 was found to be a highly sensitive (275/424, 64.86%) marker in the diagnosis of PTC, but was found to be expressed only in a few cases involving other types of thyroid lesions (58/424, 13.68%). The odds ratio, expressed as PTC group versus other thyroid lesions group, was 13.97 (95% CI: 7.51-26.01, P<0.00001). The results also showed that the positive expression rates of galectin-3 in PTC patients with LNM were higher than those in PTC patients without LNM.

Conclusion: This meta-analysis demonstrated that galectin-3 may become a potentially useful immunomarker to distinguish between PTC and non-PTC patients. In addition, PTC patients with positive expression of galectin-3 were more prone to LNM.

Citing Articles

Lung cancer cell-derived exosomes: progress on pivotal role and its application in diagnostic and therapeutic potential.

Abdul Manap A, Ngwenya F, Kalai Selvan M, Arni S, Hassan F, Mohd Rudy A Front Oncol. 2024; 14:1459178.

PMID: 39464709 PMC: 11502357. DOI: 10.3389/fonc.2024.1459178.

Regulation of cargo selection in exosome biogenesis and its biomedical applications in cancer.

Lee Y, Shin K, Chae Y Exp Mol Med. 2024; 56(4):877-889.

PMID: 38580812 PMC: 11059157. DOI: 10.1038/s12276-024-01209-y.

Current Trends in Biohumoral Screening for the Risk of Sudden Cardiac Death: A Systematic Review.

Isaila O, Moroianu L, Hostiuc S Medicina (Kaunas). 2024; 60(3).

PMID: 38541144 PMC: 10972295. DOI: 10.3390/medicina60030418.

Dual targeting of MAPK and PI3K pathways unlocks redifferentiation of Braf-mutated thyroid cancer organoids.

Lasolle H, Schiavo A, Tourneur A, Gillotay P, de Faria da Fonseca B, Ceolin L Oncogene. 2023; 43(3):155-170.

PMID: 37985676 PMC: 10786723. DOI: 10.1038/s41388-023-02889-y.

CTC, ctDNA, and Exosome in Thyroid Cancers: A Review.

Wang W, Zheng Z, Lei J Int J Mol Sci. 2023; 24(18).

PMID: 37762070 PMC: 10530859. DOI: 10.3390/ijms241813767.

References

Gomez Saez J . Diagnostic and prognostic markers in differentiated thyroid cancer. Curr Genomics. 2012; 12(8):597-608. PMC: 3271312. DOI: 10.2174/138920211798120826. View

Barut F, Onak Kandemir N, Bektas S, Bahadir B, Keser S, Ozdamar S . Universal markers of thyroid malignancies: galectin-3, HBME-1, and cytokeratin-19. Endocr Pathol. 2010; 21(2):80-9. DOI: 10.1007/s12022-010-9114-y. View

Bartolazzi A, Gasbarri A, Papotti M, Bussolati G, Lucante T, Khan A . Application of an immunodiagnostic method for improving preoperative diagnosis of nodular thyroid lesions. Lancet. 2001; 357(9269):1644-50. DOI: 10.1016/s0140-6736(00)04817-0. View

Than T, Swethadri G, Wong J, Ahmad T, Jamil D, Maganlal R . Expression of Galectin-3 and Galectin-7 in thyroid malignancy as potential diagnostic indicators. Singapore Med J. 2008; 49(4):333-8. View

Salajegheh A, Dolan-Evans E, Sullivan E, Irani S, Rahman M, Vosgha H . The expression profiles of the galectin gene family in primary and metastatic papillary thyroid carcinoma with particular emphasis on galectin-1 and galectin-3 expression. Exp Mol Pathol. 2014; 96(2):212-8. DOI: 10.1016/j.yexmp.2014.02.003. View

Kawachi K, Matsushita Y, Yonezawa S, Nakano S, Shirao K, Natsugoe S . Galectin-3 expression in various thyroid neoplasms and its possible role in metastasis formation. Hum Pathol. 2000; 31(4):428-33. DOI: 10.1053/hp.2000.6534. View

Cvejic D, Savin S, Petrovic I, Paunovic I, Tatic S, Krgovic K . Galectin-3 expression in papillary microcarcinoma of the thyroid. Histopathology. 2005; 47(2):209-14. DOI: 10.1111/j.1365-2559.2005.02199.x. View

Rabinovich G . Galectin-1 as a potential cancer target. Br J Cancer. 2005; 92(7):1188-92. PMC: 2361964. DOI: 10.1038/sj.bjc.6602493. View

Liu Z, Li X, Shi L, Maimaiti Y, Chen T, Li Z . Cytokeratin 19, thyroperoxidase, HBME-1 and galectin-3 in evaluation of aggressive behavior of papillary thyroid carcinoma. Int J Clin Exp Med. 2014; 7(8):2304-8. PMC: 4161585. View

10.

Chiariotti L, Salvatore P, Frunzio R, Bruni C . Galectin genes: regulation of expression. Glycoconj J. 2004; 19(7-9):441-9. DOI: 10.1023/B:GLYC.0000014073.23096.3a. View

11.

Lin T, Chang H, Chen C, Chen C, Lin S, Hsu T . Galectin-3 Binding Protein and Galectin-1 Interaction in Breast Cancer Cell Aggregation and Metastasis. J Am Chem Soc. 2015; 137(30):9685-93. DOI: 10.1021/jacs.5b04744. View

12.

Punt S, Thijssen V, Vrolijk J, de Kroon C, Gorter A, Jordanova E . Galectin-1, -3 and -9 Expression and Clinical Significance in Squamous Cervical Cancer. PLoS One. 2015; 10(6):e0129119. PMC: 4467041. DOI: 10.1371/journal.pone.0129119. View

13.

Lavra L, Rinaldo C, Ulivieri A, Luciani E, Fidanza P, Giacomelli L . The loss of the p53 activator HIPK2 is responsible for galectin-3 overexpression in well differentiated thyroid carcinomas. PLoS One. 2011; 6(6):e20665. PMC: 3117790. DOI: 10.1371/journal.pone.0020665. View

14.

Lee Y, Lee J . Prognostic value of epidermal growth factor receptor, p53 and galectin-3 expression in papillary thyroid carcinoma. J Int Med Res. 2013; 41(3):825-34. DOI: 10.1177/0300060513477312. View

15.

Htwe T, Karim N, Wong J, Jahanfar S, Mansur M . Differential expression of galectin-3 in advancing thyroid cancer cells: a clue toward understanding tumour progression and metastasis. Singapore Med J. 2010; 51(11):856-9. View

16.

Gong L, Chen P, Liu X, Han Y, Zhou Y, Zhang W . Expressions of D2-40, CK19, galectin-3, VEGF and EGFR in papillary thyroid carcinoma. Gland Surg. 2014; 1(1):25-32. PMC: 4115709. DOI: 10.3978/j.issn.2227-684X.2012.03.02. View

17.

Erdem H, Gundogdu C, Sipal S . Correlation of E-cadherin, VEGF, COX-2 expression to prognostic parameters in papillary thyroid carcinoma. Exp Mol Pathol. 2011; 90(3):312-7. DOI: 10.1016/j.yexmp.2011.01.008. View

18.

Volante M, Bozzalla-Cassione F, Orlandi F, Papotti M . Diagnostic role of galectin-3 in follicular thyroid tumors. Virchows Arch. 2004; 444(4):309-12. DOI: 10.1007/s00428-004-0993-5. View

19.

Selemetjev S, Savin S, Paunovic I, Tatic S, Cvejic D . Changes in the expression pattern of apoptotic molecules (galectin-3, Bcl-2, Bax, survivin) during progression of thyroid malignancy and their clinical significance. Wien Klin Wochenschr. 2014; 127(9-10):337-44. DOI: 10.1007/s00508-014-0674-6. View

20.

Bernet V, Anderson J, Vaishnav Y, Solomon B, Adair C, Saji M . Determination of galectin-3 messenger ribonucleic Acid overexpression in papillary thyroid cancer by quantitative reverse transcription-polymerase chain reaction. J Clin Endocrinol Metab. 2002; 87(10):4792-6. DOI: 10.1210/jc.2002-020390. View